Sinopharm Group Co., Ltd. (OTCMKTS:SHTDY) is one of China’s largest integrated healthcare companies and an indirect subsidiary of the state-owned China National Pharmaceutical Group Co., Ltd. The company operates through two primary segments—pharmaceutical distribution and retail pharmacy—offering comprehensive supply chain solutions that span procurement, storage, transportation and sales of medical products. With a broad portfolio that includes prescription drugs, over-the counter medicines, medical devices and consumables, Sinopharm serves hospitals, clinics, retail pharmacies and other healthcare institutions across mainland China.
In its distribution business, Sinopharm leverages an extensive logistics network, comprising hundreds of distribution centers and thousands of delivery vehicles, to ensure timely delivery of pharmaceuticals under stringent temperature-controlled conditions. The retail segment operates both company-owned and franchised pharmacies, providing consumers with access to general medicines, health supplements, diagnostic testing services and basic medical consultations. The group also engages in contract manufacturing of bulk pharmaceutical ingredients and finished dosage formulations, and maintains strategic partnerships for the research, development and commercialization of vaccines and biologics.
Founded in 1998 and listed on the Shanghai Stock Exchange in December 2009 as one of the first A-share pharmaceutical companies, Sinopharm has continually expanded its footprint beyond China, establishing subsidiaries and joint ventures in Asia, Europe, the Middle East and Africa. The company is governed by a board of directors and senior management team tasked with navigating regulatory landscapes and advancing innovation in healthcare delivery. Through ongoing investment in digital supply chain technologies and strategic alliances, Sinopharm aims to enhance accessibility and affordability of medical products for a rapidly aging population.
AI Generated. May Contain Errors.
